92 related articles for article (PubMed ID: 8958803)
1. Expression of Met protein in thyroid tumours.
Ruco LP; Ranalli T; Marzullo A; Bianco P; Prat M; Comoglio PM; Baroni CD
J Pathol; 1996 Nov; 180(3):266-70. PubMed ID: 8958803
[TBL] [Abstract][Full Text] [Related]
2. Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis.
Ruco LP; Stoppacciaro A; Ballarini F; Prat M; Scarpino S
J Pathol; 2001 May; 194(1):4-8. PubMed ID: 11329134
[TBL] [Abstract][Full Text] [Related]
3. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid.
Zanetti A; Stoppacciaro A; Marzullo A; Ciabatta M; Fazioli F; Prat M; Comoglio PM; Baroni CD; Ruco LP
J Pathol; 1998 Nov; 186(3):287-91. PubMed ID: 10211118
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas.
Harvey P; Warn A; Newman P; Perry LJ; Ball RY; Warn RM
J Pathol; 1996 Dec; 180(4):389-94. PubMed ID: 9014859
[TBL] [Abstract][Full Text] [Related]
5. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
6. COX-2 is induced by HGF stimulation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness.
Scarpino S; Duranti E; Stoppacciaro A; Pilozzi E; Natoli G; Sciacchitano S; Luciani E; Ruco L
J Pathol; 2009 Aug; 218(4):487-94. PubMed ID: 19391129
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid.
Scarpino S; Cancellario d'Alena F; Di Napoli A; Pasquini A; Marzullo A; Ruco LP
J Pathol; 2004 Mar; 202(3):352-8. PubMed ID: 14991901
[TBL] [Abstract][Full Text] [Related]
8. Expression and localization of HGF and met in Wilms' tumours.
Alami J; Williams BR; Yeger H
J Pathol; 2002 Jan; 196(1):76-84. PubMed ID: 11748645
[TBL] [Abstract][Full Text] [Related]
9. Expression and significance of c-met protein in papillary thyroid carcinoma.
Inaba M; Sato H; Abe Y; Umemura S; Ito K; Sakai H
Tokai J Exp Clin Med; 2002 Aug; 27(2):43-9. PubMed ID: 12472169
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroid.
Scarpino S; Stoppacciaro A; Colarossi C; Cancellario F; Marzullo A; Marchesi M; Biffoni M; Comoglio PM; Prat M; Ruco LP
J Pathol; 1999 Dec; 189(4):570-5. PubMed ID: 10629560
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells.
Scarpino S; Di Napoli A; Taraboletti G; Cancrini A; Ruco LP
J Pathol; 2005 Jan; 205(1):50-6. PubMed ID: 15526350
[TBL] [Abstract][Full Text] [Related]
12. Difference in patterns of Met expression in papillary thyroid carcinomas and nonneoplastic thyroid tissue.
Fluge Ø ; Haugen DR; Lillehaug JR; Varhaug JE
World J Surg; 2001 May; 25(5):623-31. PubMed ID: 11369990
[TBL] [Abstract][Full Text] [Related]
13. Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases.
Belfiore A; Gangemi P; Costantino A; Russo G; Santonocito GM; Ippolito O; Di Renzo MF; Comoglio P; Fiumara A; Vigneri R
J Clin Endocrinol Metab; 1997 Jul; 82(7):2322-8. PubMed ID: 9215314
[TBL] [Abstract][Full Text] [Related]
14. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma.
Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
Hepatology; 1997 Mar; 25(3):619-23. PubMed ID: 9049208
[TBL] [Abstract][Full Text] [Related]
15. Met overexpression confers HGF-dependent invasive phenotype to human thyroid carcinoma cells in vitro.
de Luca A; Arena N; Sena LM; Medico E
J Cell Physiol; 1999 Sep; 180(3):365-71. PubMed ID: 10430176
[TBL] [Abstract][Full Text] [Related]
16. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules.
Trovato M; Villari D; Bartolone L; Spinella S; Simone A; Violi MA; Trimarchi F; Batolo D; Benvenga S
Thyroid; 1998 Feb; 8(2):125-31. PubMed ID: 9510120
[TBL] [Abstract][Full Text] [Related]
17. Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells.
Scarpino S; Di Napoli A; Melotti F; Talerico C; Cancrini A; Ruco L
J Pathol; 2007 Aug; 212(4):411-9. PubMed ID: 17573672
[TBL] [Abstract][Full Text] [Related]
18. Differentiated thyroid carcinomas with vascular invasion: a comparative study of follicular, Hürthle cell and papillary thyroid carcinoma.
Mai KT; Khanna P; Yazdi HM; Perkins DG; Veinot JP; Thomas J; Lamba M; Nair BD
Pathology; 2002 Jun; 34(3):239-44. PubMed ID: 12109784
[TBL] [Abstract][Full Text] [Related]
19. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
[TBL] [Abstract][Full Text] [Related]
20. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
